Multi-site, Real-world Study of the Impact of Rituximab on Physiologic Outcomes for Anti-neutrophil Cytoplasmic Antibody Associated Interstitial Lung Disease
A104. ADVANCES IN THE DIAGNOSIS AND TREATMENT OF ILD | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A2853-A2853
10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2853